{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:43:05Z","timestamp":1760236985600,"version":"build-2065373602"},"reference-count":23,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T00:00:00Z","timestamp":1580688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Discovery of insulin in 1921 changed the lives of patients with type 1 diabetes (T1DM) forever. What had been a death sentence became a manageable, albeit chronic, disease. Insulin did not cure the disease, as it did not address the actual disease process, but instead treated its sequelae, namely elevated blood sugars. Importantly, insulin administration fails to ensure normoglycaemia. Even with the most sophisticated \u2018near closed-loop\u2019 methods, glucose homeostasis is not restored to normal. T1DM patients face complications, both short-term, such as hypo- and hyperglycaemia, and long-term, with increased glycosylation of proteins leading to eye, kidney, nervous system and other sequelae. These complications are associated with significant morbidity and mortality even after intensive insulin treatment. Nearly 100 years after the discovery of insulin, we continue to face the challenge of addressing the disease process itself, in order to fundamentally improve the life of these patients. There are major efforts to achieve just that: to completely arrest the autoimmune process destroying the insulin-producing cells in the pancreas, or at least significantly slow the process to blunt and delay short- and long-term complications. The aim of this Communication is to propose a novel assessment tool that would serve as a quantitative outcome measure by which therapies, short of clinical cure, may be compared and their true benefit to the treatment of diabetes assessed.<\/jats:p>","DOI":"10.3390\/ijms21030992","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T11:28:31Z","timestamp":1580729311000},"page":"992","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Novel Quantitative Approach to Staging and Assessing Recovery from Type 1 Diabetes Mellitus: The Type 1 Diabetes Mellitus Metabolic Recovery Index"],"prefix":"10.3390","volume":"21","author":[{"given":"Tihamer","family":"Orban","sequence":"first","affiliation":[{"name":"DMNoMore\/Phaim Ltd., Office 227, Chester House, 81-83 Fulham High Street, Fulham, London SW6 3JA, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nara T.","family":"Orban","sequence":"additional","affiliation":[{"name":"DMNoMore\/Phaim Ltd., Office 227, Chester House, 81-83 Fulham High Street, Fulham, London SW6 3JA, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heyam","family":"Jalahej","sequence":"additional","affiliation":[{"name":"DMNoMore\/Phaim Ltd., Office 227, Chester House, 81-83 Fulham High Street, Fulham, London SW6 3JA, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piers E. F.","family":"Daubeney","sequence":"additional","affiliation":[{"name":"DMNoMore\/Phaim Ltd., Office 227, Chester House, 81-83 Fulham High Street, Fulham, London SW6 3JA, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,3]]},"reference":[{"key":"ref_1","first-page":"141","article-title":"Pancreatic Extracts in the Treatment of Diabetes Mellitus","volume":"12","author":"Banting","year":"1922","journal-title":"Can. Med. Assoc. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s00125-016-4022-4","article-title":"Coming of age: The artificial pancreas for type 1 diabetes","volume":"59","author":"Thabit","year":"2016","journal-title":"Diabetologia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/dom.12501","article-title":"Plasma insulin profiles after subcutaneous injection: How close can we get to physiology in people with diabetes?","volume":"17","author":"Home","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/archinternmed.2011.16","article-title":"Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: An analysis of the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications cohort","volume":"171","author":"Rue","year":"2011","journal-title":"Arch. Intern. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2337\/db09-1216","article-title":"Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT\/EDIC: Comparison of adults and adolescents","volume":"59","author":"White","year":"2010","journal-title":"Diabetes"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2337\/dc09-1941","article-title":"Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study","volume":"33","author":"Albers","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_7","first-page":"111","article-title":"Autoimmune beta cell insufficiency","volume":"23","author":"Eisenbarth","year":"1984","journal-title":"Triangle"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/cei.12672","article-title":"CD4 T cell differentiation in Type 1 Diabetes","volume":"183","author":"Walker","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coi.2013.10.011","article-title":"The central role of antigen presentation in islets of Langerhans in autoimmune diabetes","volume":"26","author":"Calderon","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2249.2012.04635.x","article-title":"CD8 T cell autoreactivity to preproinsulin epitopes with very low human leucocyte antigen class I binding affinity","volume":"170","author":"Abreu","year":"2012","journal-title":"Clin. Exp. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2213-8587(13)70065-2","article-title":"Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial","volume":"1","author":"Gitelman","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1056\/NEJMoa043980","article-title":"Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes","volume":"352","author":"Keymeulen","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0140-6736(11)60886-6","article-title":"Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled trial","volume":"378","author":"Orban","year":"2011","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","article-title":"Rituximab, B-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.4049\/jimmunol.166.8.5265","article-title":"Intermolecular Antigen Spreading Occurs During the Preclinical Period of Human Type 1 Diabetes","volume":"166","author":"Gersuk","year":"2001","journal-title":"J. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.2337\/diacare.28.5.1068","article-title":"Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial\u2014Type 1","volume":"28","author":"Skyler","year":"2005","journal-title":"Diabetes Care"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00125-016-4122-1","article-title":"GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: Findings from a Bayesian meta-analysis","volume":"60","author":"Beam","year":"2016","journal-title":"Diabetologia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jaut.2009.10.005","article-title":"Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy","volume":"34","author":"Orban","year":"2010","journal-title":"J. Autoimmun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2337\/dc14-2787","article-title":"The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months","volume":"38","author":"Sosenko","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2337\/dc14-1813","article-title":"A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history","volume":"38","author":"Sosenko","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00125-013-2960-7","article-title":"The use of intermediate endpoints in the design of type 1 diabetes prevention trials","volume":"56","author":"Krischer","year":"2013","journal-title":"Diabetologia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(11)60895-7","article-title":"Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: A randomised double-blind trial","volume":"378","author":"Wherrett","year":"2011","journal-title":"Lancet"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/3\/992\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:54:04Z","timestamp":1760172844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/3\/992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,3]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["ijms21030992"],"URL":"https:\/\/doi.org\/10.3390\/ijms21030992","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2020,2,3]]}}}